{"id":29480,"date":"2026-07-01T20:58:00","date_gmt":"2026-07-01T18:58:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=5d05c38d1e7226e2e3ece30e21f0fb4f"},"modified":"2026-07-01T20:58:00","modified_gmt":"2026-07-01T18:58:00","slug":"92bio-inc-doses-first-patient-in-phase-1-clinical-trial-of-ntb-928-in-platinum-resistant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=29480","title":{"rendered":"92Bio, Inc. Doses First Patient in Phase 1 Clinical Trial of NTB-928 in Platinum-Resistant Ovarian Cancer"},"content":{"rendered":"

\n\u2014 NTB-928 is a bispecific T-cell engager engineered for selective killing of FOLR1-overexpressing tumor cells while sparing FOLR1-positive normal tissues \u2014<\/i><\/p><\/a><\/a>

HAYWARD, Calif.--(BUSINESS WIRE)--92Bio, Inc. (www.92biotech.com<\/a>), a clinical-stage biotechnology company developing next-generation T-cell engaging antibodies (TCEs), today announced dosing of the first patient in a Phase 1 clinical trial evaluating NTB-928 for the treatment of platinum-resistant ovarian cancer. The trial is being conducted at multiple US sites, with the first patient dosed at START New York-Long Island under the direction of Principal Investigator Dr. Geraldine O'Sullivan Coyne, MD.<\/p>

\nNTB-928 combines an affinity-tuned anti-CD3 moiety with an avidity-dependent FOLR1-binding arm for tumor versus normal selectivity. The dual-mechanism design enables potent killing of FOLR1-overexpressing ovarian cancer cells while sparing normal tissues that express trace FOLR1\u2014a key limitation of conventional approaches targeting this antigen. Notably, FOLR1 is overexpressed in greater than 75% of ovarian cancer. Preclinical data supporting NTB-928's differentiated selectivity profile have been published in Oncoimmunology<\/i> (Avanzino et al., 2022<\/a>).<\/p>

\nThe ongoing Phase 1, single-arm, open-label trial utilizes a Bayesian Optimal Interval dose-escalation design with backfill (BOIN-BF) to evaluate the safety, tolerability, and preliminary activity of NTB-928.<\/p>

\n\"Dosing the first patient in this study is a defining moment for 92Bio,\" said Ben Buelow, MD, PhD, Chief Executive Officer of 92Bio. \"NTB-928 was purpose-built to solve the selectivity challenge that has constrained FOLR1 targeted T-cell engagers in ovarian cancer. Its unique combination of affinity-tuned CD3 engagement and avidity-dependent FOLR1 binding positions it specifically as a best-in-class candidate for patients with ovarian cancer, and generally for FOLR1-positive malignancies beyond that.\"<\/p>

\n\u201cThe initiation of this study represents an important step forward in evaluating a novel approach for patients with platinum-resistant ovarian cancer, where significant unmet needs remain,\u201d said Geraldine O'Sullivan Coyne, MD, Principal Investigator at START New York-Long Island who dosed the first patient. \u201cWe are proud to support the clinical development of NTB-928 and grateful for the strong collaboration between START, 92Bio, and Northwell Health Cancer Institute. Milestones like this are only possible through a shared commitment to advancing research and expanding opportunities for patients.\u201d<\/p>

\nAbout NTB-928<\/b><\/p>

\nNTB-928 is a fully human bispecific T-cell engaging antibody targeting FOLR1 and CD3. Its selectivity derives from two synergistic design features: an affinity-tuned anti-CD3 arm that drives potent anti-tumor T-cell activation with reduced cytokine secretion, and a bivalent FOLR1-binding arm that confers avidity-dependent binding to tumor cells overexpressing FOLR1 but not to normal cells expressing trace FOLR1. Neither feature alone is sufficient for selectivity; both are required. In preclinical studies, NTB-928 demonstrated robust tumor clearance in vitro<\/i>, ex vivo <\/i>and in vivo<\/i> with a favorable safety profile (Avanzino BC et al., Oncoimmunology<\/i>, 2022; doi: 10.1080\/2162402X.2022.2113697).<\/p>

\nAbout 92Bio, Inc.<\/b><\/p>

\n92Bio, Inc. is a clinical-stage biotechnology company focused on developing differentiated T-cell engaging antibodies for the treatment of hematologic and solid tumors. The company's proprietary platform enables the engineering of bispecific antibodies with tumor-selective binding profiles designed to maximize efficacy while minimizing on-target, off-tumor toxicity. 92Bio is headquartered in Hayward, CA.<\/p> Contacts<\/b>

\nBen Buelow, MD, PhD. CEO, 92Bio. bbuelow@92biotech.com<\/a>; 206-714-4469<\/p>","protected":false},"excerpt":{"rendered":"

\u2014 NTB-928 is a bispecific T-cell engager engineered for selective killing of FOLR1-overexpressing tumor cells while sparing FOLR1-positive normal tissues \u2014HAYWARD, Calif.–(BUSINESS WIRE)–92Bio, Inc. (www.92biotech.com), a clinical-stage biotechnolog…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-29480","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29480"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29480\/revisions"}],"predecessor-version":[{"id":29481,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29480\/revisions\/29481"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}